-
Promising anti-aging drug fails to live up to the hype
25 Sep 2025 08:50 GMT
… that taking low-dose rapamycin or related drugs (called rapalogs) … adults, leading to increased vaccine responses and reduced biomarkers … The largest follow-up trials didn’t consistently replicate … drug may depend on age or exercise status. A small trial …
-
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
24 Sep 2025 10:00 GMT
… a Phase 2 trial evaluating QTORIN™ rapamycin for clinically … .S. Food and Drug Administration (FDA)-approved therapies, today … to evaluate QTORIN™ rapamycin for the treatment of clinically significant … ongoing and planned clinical trials and ongoing and planned …
-
Hanmi Reveals Promising Preclinical Results for Obesity Drug
23 Sep 2025 13:03 GMT
Hanmi Pharmaceutical announced on Sept. 23 that its obesity drug candidate HM17321 demonstrated … of the mammalian target of rapamycin (mTOR) pathway and glycolysis-dependent … existing obesity treatments.
Choi In-young, head of Hanmi Pharmaceutical R…
-
Hanmi Pharmaceuticals gets attention with world’s 1st 'muscle-building' obesity drug
23 Sep 2025 06:55 GMT
… muscle-building” obesity treatment.
Korean drugmaker said Tuesday it has … mechanistic target of the rapamycin pathway and promoting … enter Phase 1 clinical trial, replicating pharmacological efficacy … by the news, Hanmi Pharmaceutical';s stock price …
-
A Narrative Review of Phase II and III Clinical Trials for the Pharmacological Treatment of Fibrodysplasia Ossificans Progressiva (FOP): Efficacy, Safety, and Challenges in Treatment Strategies
22 Sep 2025 13:16 GMT
… , mTOR inhibitors like rapamycin, gene therapy strategies, … brief summary, intervention (medication), primary outcome measures, age … II and III trials of pharmacological treatments for FOP. … Kaplan FS. Druggable targets, clinical trial design and proposed …
-
Identification and Validation of Hub Genes in Hidradenitis Suppurativa
24 Sep 2025 16:07 GMT
… The following drugs are not used in HS treatment based on … the drug-gene interaction database for precision medicine and drug discovery … al. Mammalian target of rapamycin, insulin resistance and hidradenitis … Jun/MMPs. Acta pharmaceutica. 2024;74(3):461– …
-
Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset
22 Sep 2025 15:02 GMT
… mTOR (mammalian target of rapamycin) pathways. mTOR is a … radiprodil, an investigational drug currently being studied in … partnered with JCR Pharmaceuticals, a Japanese biotech company with a … despite the treatment with two anti-seizure medications.iii Angelini …
-
Angelini Pharma sigla un accordo di opzione esclusiva con Sovargen per ottenere i diritti globali di sviluppo e commercializzazione di un asset innovativo nell'ambito della salute del cervello
22 Sep 2025 15:02 GMT
… mTOR (mammalian target of rapamycin), un target geneticamente validato … una collaborazione con JCR Pharmaceuticals, una biotech giapponese, per una … D, Kwan P. Treatment Outcomes in Patients With Newly … Established and New Antiepileptic Drugs: A 30-Year …
-
Want to Live Longer? First Find Out How Old You Really Are
25 Sep 2025 20:50 GMT
… Vaughan hope to pinpoint treatments and lifestyle changes to … formerly chaired its department of medicine.
The Institute intends to … a stress-reduction program or rapamycin or metformin or Ozempic. … have enrolled in clinical trials and we underwrite those …
-
Low-Dose IL-2 Attenuates Neuropathic Pain via Treg Expansion in Rats
25 Sep 2025 14:06 GMT
… Committee of Peking Union Medical College Hospital (Beijing, China … further investigation in human trials for neuropathic pain.
Figure … and regulatory T cell treatments attenuate punctate and dynamic … R, et al. Rapamycin reduces clinical signs and neuropathic …
About
© 1995-2025